Pan-RAF:MEK Molecular Glues Take Center Stage-Reference-Cited by-同舟云学术

Pan-RAF:MEK Molecular Glues Take Center Stage

Published:2024-07-01 Issue:7 Volume:14 Page:1143-1144
ISSN:2159-8274
Container-title:Cancer Discovery
language:en
Short-container-title:

Author:

Hangauer Matthew J.¹²^ORCID,Gutkind Jorge Silvio³²^ORCID,Ferguson Fleur M.²⁴⁵^ORCID

Affiliation:

1. Department of Dermatology, University of California San Diego, La Jolla, California. 1

2. UCSD Moores Cancer Center, University of California San Diego, La Jolla, California. 3

3. Department of Pharmacology, University of California San Diego, La Jolla, California. 2

4. Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, California. 4

5. Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California. 5

Abstract

Summary: In this issue, Ryan and colleagues describe the preclinical development of a pan-RAF:MEK molecular glue with superior efficacy, brain penetrance, and tolerability in xenograft models of Ras/Raf/MAPK pathway–driven tumors. See related article by Ryan et al., p. 1190 (1).

Publisher

American Association for Cancer Research (AACR)

Link

https://aacrjournals.org/cancerdiscovery/article-pdf/14/7/1143/3470079/cd-24-0539.pdf

Reference7 articles.

1. The pan-RAF-MEK non degrading molecular glue NST-628 is a potent and brain penetrant inhibitor of the RAS-MAPK pathway with activity across diverse RAS- and RAF-driven cancers;Ryan;Cancer Discov,2024

2. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF;Wan;Cell,2004

3. The rise of molecular glues;Schreiber;Cell,2021

4. Live-cell target engagement of allosteric MEKi on MEK-RAF/KSR-14-3-3 complexes;Marsiglia;Nat Chem Biol,2024

5. Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer;McNamara;Gynecol Oncol,2024 9